Abstract: The invention relates to the field of binding molecules comprising at least one single variable antibody domain, targeted at receptors present on myofibroblasts and/or hepatic stellate cells (HSCs). The invention also relates to a binding molecule comprising at least two single variable antibody domains, each targeting a receptor on HSCs and/or on myofibroblasts. The invention further relates to nucleic acids encoding such binding molecules, a host cell for expression of such binding molecules and to methods for preparing such binding molecules. The invention further relates to pharmaceutical compositions that comprise such binding molecule and to uses of such binding molecules and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.

Abstract: A first aspect of the disclosure relates to a method for preparing cell-targeting conjugates by coupling at least one functional moiety, such as a therapeutic compound, diagnostic compound or chelating agent to a targeting moiety. A second aspect of this disclosure relates to the cell-targeting conjugates obtainable with this method. A third aspect of the disclosure described herein relates to pharmaceutical compositions comprising the cell-targeting conjugates.

Abstract: This disclosure describes a method for preparing stable cell targeting conjugates. A further aspect of this disclosure relates to the stable cell targeting conjugates obtainable by the method and to pharmaceutical compositions comprising these stable cell targeting conjugates. A last aspect of this disclosure relates to the use of these conjugates and pharmaceutical compositions as a medicament.

Abstract: Cell targeting conjugates that comprise a targeting moiety and one or more functional moieties bound thereto via a linker, wherein the linker comprises a transition metal complex and wherein at least 90% of the conjugates have a ratio of functional moieties to targeting moieties (DAR) of or less. A pharmaceutical composition comprising the cell targeting conjugates and the use of the conjugates and composition as a medicament, in particular, in the treatment of cancer.